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Abstract
Myeloid-derived suppressor cells (MDSCs) are immature myeloid
cells with strong immunosuppressive activity that promote tumor
growth. In this study, we describe a mechanism by which cancer
cells control MDSCs in human cancers by upregulating TRF2, a pro-
tein required for telomere stability. Specifically, we showed that
the TRF2 upregulation in cancer cells has extratelomeric roles in
activating the expression of a network of genes involved in the
biosynthesis of heparan sulfate proteoglycan, leading to profound
changes in glycocalyx length and stiffness, as revealed by atomic
force microscopy. This TRF2-dependent regulation facilitated the
recruitment of MDSCs, their activation via the TLR2/MyD88/IL-6/
STAT3 pathway leading to the inhibition of natural killer recruit-
ment and cytotoxicity, and ultimately tumor progression and
metastasis. The clinical relevance of these findings is supported by
our analysis of cancer cohorts, which showed a correlation
between high TRF2 expression and MDSC infiltration, which was
inversely correlated with overall patient survival.
Keywords HSPG; immunosurveillance; MDSC; NK cells; TRF2
Subject Categories Cancer; Cell Adhesion, Polarity & Cytoskeleton;
Immunology
DOI 10.15252/embj.2018100012 | Received 8 June 2018 | Revised 10 March
2019 | Accepted 15 March 2019 | Published online 18 April 2019
The EMBO Journal (2019) 38: e100012
Introduction
Telomeres are key features of linear chromosomes that preserve
genome stability and function. Variations in the telomere state are
critical for cell senescence, stem cell biology, and cancer develop-
ment (Blackburn et al, 2015). Human telomeres are composed of
repeated TTAGGG DNA sequences and require the enzyme telom-
erase for full replication (Gilson & Ge´li, 2007). To prevent unwanted
activation of the DNA Damage Response (DDR), telomeric DNA is
associated with shelterin, a protein complex composed of six
different subunits (TRF1, TRF2, RAP1, TIN2, TPP1, and POT1
(Giraud-Panis et al, 2013). During oncogenesis, telomere shortening
is associated with apparent antagonistic outcomes; it both favors
cancer initiation through mechanisms involving genome instability
(Artandi et al, 2000) and prevents cancer progression by activating
the DNA Damage Response (DDR) checkpoint to behave as a cell-
intrinsic proliferation barrier (Gonza´lez-Sua´rez et al, 2000). Conse-
quently, telomerase reactivation is crucial for cancer progression and
nearly 90% of human cancers exhibit upregulation of telomerase
(Kim et al, 1994). Therefore, telomeres are considered potential anti-
cancer targets; to date, most studies of telomeres have focused on
cell-intrinsic proliferation barriers initiated by telomerase inhibition
(Jafri et al, 2016) and more recently TRF1 inhibition (Bejarano et al,
2017). A disadvantage of these therapeutic approaches is the pro-
aging effects of telomere deprotection in normal tissues.
The expression of the key shelterin subunit TRF2 is regulated by
several cancer-associated signaling molecules including p53 (Fujita
et al, 2010), Wnt/b-catenin (Diala et al, 2013), and WT1 (Wagner
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et al, 2014) and has been reported to be upregulated in a large panel of
human cancers, in association with poor prognosis (Nakanishi et al,
2003; Diehl et al, 2011; Biroccio et al, 2013; Benhamou et al, 2016). In
various mouse models, TRF2 inhibition has been shown to impair
tumorigenesis independently of its functions in telomere protection
and maintenance, but via cell extrinsic effects on immunosurveillance
and angiogenesis, suggesting TRF2 to be a potential target in anti-
cancer therapies without pro-aging telomere deprotective effects
(Biroccio et al, 2013; El Maı¨ et al, 2014; Zizza et al, 2019). However,
the mechanisms by which TRF2 exerts these multiple oncogenic func-
tions, as well as their impact on overall survival (OS), tumor relapse,
metastasis, or treatment response remain largely unknown.
An efficient antitumor immune response is of paramount impor-
tance to restrain cancer progression and metastasis, as well as for
successful chemotherapy or immunotherapy (Fridman et al, 2017).
Because cancer cells possess a variety of sophisticated mechanisms
to bypass their recognition and elimination by the immune system
(Vesely et al, 2011), targeting these pathways represents an
unprecedented opportunity for cancer treatment (Galluzzi et al,
2015; Restifo et al, 2016). Among the immunosuppressive proper-
ties of tumors, the recruitment and activation of myeloid-derived
suppressor cells (MDSCs) facilitate cancer progression (Veglia et al,
2018). Although the role of systemic and cancer-associated inflam-
mation in this process has been established (Ostrand-Rosenberg &
Fenselau, 2018), little is known about the specific pathways by
which cancer cells control the immunosuppressive functions of
MDSCs and how the cell-surface molecules of cancer cells can trig-
ger MDSC activation; in particular, the impact of the extracellular
matrix and glycocalyx in cancer tissues on MDSC remains elusive.
Previously, we revealed the role of TRF2 in the regulation of the
HS3ST4 gene, which encodes an enzyme involved in the sulfation of
the heparin sulfate moiety of proteoglycans, preventing the recruit-
ment of natural killer (NK) cells (Biroccio et al, 2013). However, we
were unable to decipher the mechanism by which HS3ST4 expres-
sion and possibly heparin sulfate proteoglycan (HSPG) biosynthesis
keep NK cell activation in check. In this study, we analyzed the
tumor immune microenvironment of TRF2 overexpressing tumors
in innate immunity competent nude mice xenografted with human
transformed fibroblasts (Hahn et al, 1999; Hahn & Weinberg, 2002)
and in fully immunocompetent mice grafted with mouse melanoma
cells (B16F10) (Cheli et al, 2012). We found that cancer cells
recruited and directly activated MDSCs in a TRF2-dependent man-
ner, dampening NK and CD8+ T cell cytotoxicity. Moreover, we
showed that this MDSC function of TRF2 was associated with its
ability to control the glycocalyx structure by acting as a master regu-
lator of the transcription of three genes involved in HSPG biosynthe-
sis. Overall, our results reveal an immunosuppressive mechanism
linking the telomeric factor TRF2 to the glycocalyx and MDSCs,
which suggests that targeting TRF2 can counteract the immune
escape of cancer cells without inducing telomere deprotection.
Results
TRF2 triggers an immunosuppressive tumor microenvironment
Using the B16F10 melanoma mouse model, we analyzed the effects
of TRF2 on intratumoral immune cell infiltration (Fig 1A). Ten days
after tumor injection, TRF2 overexpression (conversely, TERF2
knockdown) did not affect global immune cell infiltration (CD45+)
or global CD4+, CD3+, or CD8+ T cell infiltration (Fig EV1A). How-
ever, intratumoral MDSC infiltration (CD11bHi GR1Hi expressing
cells) was strongly dependent on the level of TRF2; its upregulation
increased MDSC infiltration by approximately 2.5-fold, whereas its
downregulation decreased infiltration (Fig 1A). Notably, the intratu-
moral ratio between the two MDSC subpopulations (polymorpho-
nuclear MDSCs [PMN-MDSCs] and monocytic MDSCs [M-MDSCs])
was consistent with the findings of a previous report (Fig EV2E and
F; Kumar et al, 2016b). Upon TRF2 upregulation, this ratio shifted
toward more PMN-MDSCs (Fig EV2E and F). In addition to MDSC
infiltration, TRF2 upregulation (or downregulation) increased (or
decreased), respectively, CD25+ Foxp3+ regulatory T cell (Treg) infil-
tration and decreased (or increased), respectively, activated CD25+
Foxp3–T cell infiltration (Fig EV1B and C) and NK cell recruitment
(Fig EV1D). Similarly, xenografted tumors derived from immortalized
RasV12 human skin fibroblasts (named BJcl2; Biroccio et al, 2013)
injected into nude mice, which are immunodeficient for T cells
compartment but still have an active innate immunity including NK
cells, exhibited increased or decreased infiltration of MDSCs upon
TRF2 overexpression or knockdown, respectively (Fig EV1E).
We used a Matrigel plug assay to analyze the early immune
responses triggered by cancer cells with various TRF2 expression
levels (Fig 1B). As observed in tumors, overexpression (knock-
down) of TRF2 increased (or decreased) MDSC recruitment, respec-
tively (Figs 1C and EV1F). In addition, using phosphorylated STAT3
(pSTAT3) as a marker for MDSC activation and known regulator of
the immunosuppressive functions of MDSC (Marvel & Gabrilovich,
2015), we observed that the TRF2 level was correlated with MDSC
activation (Figs 1D and F, and EV1F). The proportion of IFN-c+ NK
cells was negatively correlated (R2 = 0.5117, P = 0.0003) with the
pSTAT3 level in MDSCs and with TRF2 expression in cancer cells
(Fig 1F), indicating that TRF2-dependent MDSC recruitment in vivo
is associated with inhibition of NK cell cytotoxicity. In the same
Matrigel plug assay, we observed that the expression of three
immunosuppressive molecules, arginase 1 (Arg-1), IL-10, and TGF-b
(Ostrand-Rosenberg & Fenselau, 2018), which are expressed by
MDSCs to trigger NK and T cell suppression (Gabrilovich & Nagaraj,
2009; Nagaraj & Gabrilovich, 2012; Sceneay et al, 2012), is upregu-
lated when TRF2 is overexpressed (Fig EV1G) and is correlated with
the level of pSTAT3 in infiltrating MDSCs (Fig 1G–I; r2 = 0.7077,
P < 0.0001 for arg-1; r2 = 0.3669, P = 0.0046 for tgf-b; r2 = 0.7418,
P < 0.0001 for il-10). Overall, these results show, using a tumor
growth experiment or Matrigel plug assay with B16F10 mouse mela-
noma cells implanted into immunocompetent mice and human
BJcl2 cells xenografted in Nude mice that a high level of TRF2 in
cancer cells induces a strong immunosuppressive tumor microenvi-
ronment by promoting MDSC and Treg cell infiltration and inhibit-
ing NK cell recruitment and degranulation.
TRF2 promotes tumorigenesis and metastasis in an MDSC-
dependent manner
Next, we determined whether the pro-tumorigenic and immunosup-
pressive effects of TRF2 overexpression are dependent on MDSCs.
MDSCs were selectively depleted in mice by repeated injection of
anti-GR-1 antibodies (Kumar et al, 2016a; Svoronos et al, 2017).
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Indeed, such a treatment abolished the intratumoral infiltration of
MDSCs, in particular PMN-MDSCs (Figs 2G, K and M, and EV2E
and F). The pro-tumorigenic and metastatic effects of TRF2
overexpression were obliterated in these MDSC-depleted mice
(Figs 2A–F and EV2A and B). The ability of TRF2-overexpressing
cancer cells to metastasize was strongly reduced when MDSCs were
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Figure 1. TRF2 overexpression triggers an immunosuppressive tumor microenvironment.
A B16F10 melanoma cells with either mTRF2 overexpression or knockdown were inoculated into the backs of immunocompetent mice. The percentages of
intratumoral CD11bHi GR1Hi MDSCs (n = 10 mice), CD25+ Foxp3+ regulatory T cells (Tregs), or CD25+ Foxp3-activated T cells (n = 5 mice per group) among CD45+
cells were analyzed by fluorescence-activated cell sorting (FACS) and represented as box plots
B–E Schematic representation of the experiment (B). TRF2-overexpressing or TRF2-knockdown BJcl2 cells were inoculated into the backs of immunodeficient mice in the
presence of Matrigel. Five days later, the percentage of immune cells infiltrating the Matrigel plugs of CD11bHi GR1Hi MDSCs (C), the intranuclear staining of
pSTAT3 (D), and CD3 NKp46+ and IFN-c+ among CD3 NKp46+ NK cells (E) were determined by FACS (n = 5 mice per group).
F–I Linear correlation plot of the percentage of IFN- c+ NK cells, the mean of fluorescence intensity (MFI) of pSTAT3 for MDSCs, and the expression of TRF2 (r2 = 0.5177;
Pearson’s correlation, P = 0.003) (F); the mRNA expression level in the Matrigel plugs of arg1, pSTAT3 MFI, and TRF2 expression (r2 = 0.7077; Pearson’s correlation,
P < 0.0001) (G); the mRNA expression level in the Matrigel plugs of tgfb, pSTAT3 MFI, and TRF2 expression (r2 = 0.3669; Pearson’s correlation, P = 0.0046) (H) and
the mRNA expression level in the Matrigel plugs of il-10, pSTAT3 MFI, and TRF2 expression (r2 = 0.7418; Pearson’s correlation, P < 0.0001) (I).
Data information: Data are presented by box plots min to max showing all points with median. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001; Mann–Whitney
test. In (F–I), Pearson correlation and P-values are indicated.
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depleted, either when we searched for natural diffusion of cancer
cells into the lungs (GFP+ cells infiltrating lungs) from a primitive
subcutaneous tumor (Figs 2C and EV2B) or when we used the clas-
sical metastasis model by intravenous injection into the tail vein
(Fig 2D–F). In both cases, MDSC depletion was sufficient to inhibit
the increased number of GFP+ cells infiltrating the lungs, the num-
ber of nodules, or the metastasis burden induced by TRF2 overex-
pression. Although MDSC depletion did not alter the infiltration of
CD45, CD3, CD4, or CD8 cells (Fig EV2C), it reversed the immuno-
suppressive tumor microenvironment created by TRF2 upregulation
(i.e., Treg cell infiltration) (Fig 2G), NK cell inhibition (Fig 2H), and
CD8+ T cell inhibition (Fig 2I). This rescue by MDSC depletion of
the TRF2-dependent immunosuppressive environment was con-
firmed by a Matrigel plug assay (Figs 2J–M and EV2F–K). Overall,
these results show that TRF2-mediated regulation of MDSCs plays a
central role in the TRF2-dependent increases in tumorigenicity and
metastasis, shaping the tumor immune microenvironment.
Cancer cells directly activate MDSCs in a TRF2-dependent
manner via the TLR2/MyD88/IL-6/STAT3 pathway
The above-mentioned results suggest that the immunosuppressive
environment controlled by the level of TRF2 in cancer cells results
from MDSC recruitment and/or activation. Therefore, we explored
whether MDSCs are directly regulated by cancer cells as a function
of the TRF2 level. We co-cultured BJcl2 or B16F10 cells in the pres-
ence or absence of TRF2 overexpression, in a mouse MDSC line
(MSC2 cells; Bruchard et al, 2012) and analyzed the pSTAT3 level
in MSC2 cells (Figs 3A and B, and EV3A–C). In TRF2-overexpres-
sing cancer cells, the pSTAT3 level was significantly increased in
MSC2 cells, whereas it was decreased after TERF2 knockdown in
cancer cells (Figs 3B and EV3C). Interestingly, when the pSTAT3
level was assayed after co-culture with conditioned medium
(Fig EV3D), we detected no differences (Fig EV3E), suggesting that
cell contact is required. Next, we investigated whether MDSCs are
activated by TRF2-overexpressing cancer cells via the Toll-like
receptor (TLR)/MyD88 pathway (Fig 3C–E). After determining the
optimal concentration of each inhibitor (Fig EV3G and H), we co-
cultured BJcl2 cancer cells in the presence or absence of TRF2 over-
expression and MSC2 cells in the presence or absence of a TLR4
antagonist (lipopolysaccharide [LPS-RS]), an anti-mouse TLR2-
blocking antibody, or a MyD88-inhibitory peptide. The blocking of
TLR4 by LPS-RS did not affect the level of pSTAT3 in MSC2 cells;
however, treatment with the anti-TLR2 antibody or anti-MyD88 pep-
tide was sufficient to inhibit the increase of pSTAT3 in MSC2 cells
co-cultured with TRF2-overexpressing cancer cells (Figs 3D and
EV3F). Since the TLR2/MyD88 pathway does not directly trigger
STAT3 phosphorylation, we explored whether activation of the
TLR2/MyD88 pathway induces a secondary signal that leads to
STAT3 phosphorylation, specifically focusing on IL-6 (Skabytska
et al, 2014). We assessed whether a mouse-specific anti-IL-6 block-
ing antibody or JAK1/2 inhibitor (Ruxolitinib) can block the
increase of STAT3 phosphorylation induced by TRF2 overexpression
(Figs 3E and EV3G and H). Adding rat IgG2a isotypic control to the
co-culture did not affect the increased pSTAT3 level; however, inhi-
bition of mouse IL-6 or JAK1/2 completely inhibited this increase.
Taken together, these data show that overexpression of TRF2 trig-
gers the TLR2/MyD88 pathway in MDSCs, which in turn favors
STAT3 phosphorylation in an IL-6/JAK1/2-dependent manner.
The TRF2-mediated activation of MDSCs inhibits NK cell function
We assessed whether the dosage of TRF2 in cancer cells affects the
immunosuppressive capacity of MDSCs on NK cell activation using
an in vitro suppression assay (Figs 3F–H and EV3J–M). The overex-
pression or knockdown of TRF2 in BJcl2 cells (Fig 3F–H) or B16F10
cells (Fig EV3J–M) was conducted in co-culture with MSC2 cells for
18 h; MSC2 cells were then sorted by fluorescence-activated cell
sorting (FACS) (Figs 3F and EV3J and K). Simultaneously, NK cells
poly I:C-primed in vivo for 18 h were sorted by FACS (Figs 3F and
EV3J and K). Sorted MSC2 and NK cells were then co-cultured for
18 h at a 1:1 ratio and finally challenged by adding the target cells
(YAK-1 or 3T3 cells) for 4 h (Figs 3F and EV3K). NK cell degranula-
tion capacity and IFN-c production were determined by flow cytom-
etry (Figs 3G and EV3L and M), and the cytotoxicity of NK cells
toward the target was assessed using a viability assay (Fig 3H).
After co-culturing MSC2 and cancer cells, we noticed that TRF2
overexpression in cancer cells increased the number of MSC2 cells
(Fig EV3I), suggesting that TRF2 enhances MDSC proliferation.
Interestingly, this proliferative effect was not altered when IL-6 was
blocked, but was strongly reduced when JAK1/2 was inhibited, sug-
gesting that TRF2 enhances MDSC proliferation in a JAK/STAT-
dependent manner. We also observed that direct co-culture of TRF2-
overexpressing cancer cells and MSC2 cells, either with BJcl2
▸Figure 2. TRF2 promotes tumorigenesis and metastasis in an MDSC-dependent manner.A–C B16F10 melanoma cells with or without mTRF2 overexpression were inoculated into the backs of immunocompetent mice and treated with anti-GR1 antibody or
isotypic control (200 lg/IP). The tumor volume was determined every 2 days using hemi-ellipsoid formula (B). On day 19 of the tumor growth experiment, the
percentages of GFP+ cells infiltrating the lungs were determined by FACS and presented as the number of GFP+ cells/mg lung tissue (C).
D–F B16F10 melanoma cells with or without mTRF2 overexpression were inoculated into tail vein of immunocompetent mice and treated with anti-GR1 antibody or
isotypic control (200 lg/IP) every 3 days. On day 21, lung metastasis was analyzed by counting macroscopic metastatic nodules and hematoxylin and eosin (H&E)
staining (E and F), scale bars = 500 lm.
G–I Tumor-infiltrating immune cells from tumors of the experiment shown in (A) were analyzed by FACS: MDSCs and CD25+ Foxp3+ Tregs (G), NK cells (H), and CD8+ T
cells (I).
J–M BJcl2 cells with or without hTRF2 overexpression were inoculated into the backs of immunodeficient nude mice and treated with anti-GR1 antibody or isotypic
control (200 lg/IP) as indicated in (J) and NK cells recruitment, degranulation, and MDSC infiltration were monitored by FACS (K-M). Density plot of CD11bHi GR1Hi
MDSC staining in control or anti-GR1-treated Matrigel plugs (K). Box plots of the percentages of infiltrating or activated NK cells (CD107a or CD69) (L), of CD11bHi
GR1Hi MDSC or NKp46+ NK cells (M) infiltrating the Matrigel plugs assay among the CD45+ cells.
Data information: Data are presented by box plots min to max showing all points with median corresponding to the percentages of each cell population among CD45+
cells or the indicated parent population or the number of lung nodules. Tumor volume is presented in mm3 along the time in days. All experiments are performed with
n = 8 mice per group; *P < 0.05, **P < 0.01, and ***P < 0.001; Mann–Whitney test.
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(Fig 3G) or with B16F10 cells (Fig EV3L and M), significantly
decreased NK cell degranulation and IFN-c production. Inversely,
TRF2 knockdown in cancer cells led to significant increases in NK
cell degranulation capacity and IFN-c production (Fig EV3L and M).
Overexpression of TRF2 not only inhibited NK cell functionality but
also strongly affected NK cell cytotoxicity (Fig 3H). Since we
observed that STAT3 phosphorylation was dependent on the IL-6/
JAK1/2 pathway, we explored whether inhibition of JAK1/2 or IL-6
was sufficient to reverse the inhibitory effect on NK cell functional-
ity. Interestingly, we observed that blocking IL-6 or JAK1/2 restored
NK cell degranulation (Fig 3G) and killing capacity (Fig 3H), which
were inhibited by TRF2 overexpression. Taken together, our data
show that direct contact between TRF2-overexpressing cancer cells
and MDSCs is sufficient to trigger TLR2 signaling, which enhances
the immunosuppressive capacity of MDSCs on NK cells via an IL-6/
JAK1/2-dependent mechanism.
TRF2 regulates the expression of ITS-associated genes involved in
glycocalyx synthesis
Next, we assessed the mechanism by which TRF2 controls the ability
of cancer cells to recruit and activate MDSCs. Because TRF2 binds an
extratelomeric range of TTAGGG repeats (ITSs) (Simonet et al, 2011;
Yang et al, 2011) to regulate the expression of HS3ST4 (Biroccio et al,
2013), a gene involved in HSPG biosynthesis, and as HSPGs shape
the tumor microenvironment and promote tumor growth (Knelson
et al, 2014; Hammond et al, 2014), we systematically searched the
genome for ITS-associated genes (Dataset EV1) involved in HSPG
biosynthesis using the Reactome online tool (http://reactome.org/Pa
thwayBrowser/) (Dataset EV2). This search revealed two ITS-asso-
ciated genes in addition to HS3ST4: VCAN, whose product activates
the TLR2 pathway (Kim et al, 2009), and GPC6, which encodes glypi-
can 6 (Dataset EV2). The expression of GPC6 and VCAN was depen-
dent on TRF2 expression, at both the RNA and protein levels (Figs 4A
and EV4A–C). These results indicate that TRF2 behaves as a tran-
scriptional regulator of three HSPG-related genes. Therefore, we
examined whether the binding of TRF2 to ITSs induces chromatin
changes involved in transcriptional regulation. Using Encode data
(Fig 4B and C), we evaluated the specific enrichment of the activating
mark H3K27ac in a large set of TRF2-bound ITSs (Figs 4B and C, and
EV4H and Dataset EV4). This specific enrichment of ITS chromatin in
H3K27ac is conserved through evolution (Fig EV4D–H and Dataset
EV3), suggesting that it plays an important role. Interestingly, almost
all the genes for which we previously revealed an ITS by TRF2 ChIP-
seq (Simonet et al, 2011) are also identified in the H3K27ac ChIP-seq
from ENCODE (Figs 4B and EV4H). We then tested whether the bind-
ing of TRF2 to ITSs triggers H3K27 acetylation and found that enrich-
ment of H3K27ac in ITSs associated with HS3ST4, VCAN, and GPC6
was decreased (increased) upon TRF2 downregulation (overexpres-
sion) (Figs 4D and EV4I). These results suggest that binding of TRF2
to ITSs converts these sequences into positive regulatory elements
that enhance the transcription of HSPG genes.
HS3ST4, GPC6, and VCAN are effectors of the MDSC-dependent
oncogenic properties of TRF2
Next, we evaluated the roles of HS3ST4, GPC6, and VCAN in TRF2-
mediated immunosuppression (Fig 5A–H and Appendix S1A–C).
We analyzed the impact of TRF2 target genes on immune infiltra-
tion (Matrigel plug assay) and observed that VCAN downregulation
decreased total immune cell infiltration, whereas downregulation of
HS3ST4 or GPC6 did not alter total immune cell infiltration
(Appendix S1B and C). However, all three genes affected MDSC or
NK cell recruitment/activation (Fig 5C and Appendix Fig S1B).
Indeed, downregulation of HS3ST4 and GPC6 significantly decreased
MDSC recruitment (Fig 5B), whereas only HS3ST4 downregulation
increased NK cell recruitment (Fig 5C). In contrast, NK cell degran-
ulation (C107a+ NK cells) was positively affected by downregula-
tion of GPC6 and VCAN but not HS3ST4 (Fig 5D), whereas only
GPC6 affected CD69+ NK cell infiltration (Fig 5E). Thus, MDSC
recruitment was mediated by HS3ST4 and GPC6, and as expected,
NK cell recruitment by HS3ST4 (Biroccio et al, 2013)), whereas NK
cell degranulation and activation were dependent on GPC6 and
VCAN. The roles of these genes in MDSC activation were confirmed
using co-culture assays, in which HS3ST4, GPC6, or VCAN expres-
sion was knocked down in TRF2-overexpressing or TRF2-downre-
gulated cancer cells (Fig 5F–H). VCAN knockdown did not affect
STAT3 phosphorylation, whereas HS3ST4 or GPC6 knockdown
decreased it. In cancer cells overexpressing TRF2, HS3ST4 or GPC6
knockdown significantly reduced the level of pSTAT3 (Fig 5G). In
addition, double knockdown of TRF2 with either HS3ST4 or GPC6
(Fig 5H) decreased the pSTAT3 level in a similar manner to that by
HS3ST4 knockdown alone, GPC6 knockdown alone, or TRF2 knock-
down alone, suggesting epistatic regulation among TRF2, HS3ST4,
and GPC6. Thus, the TRF2-dependent regulation of HS3ST4 and
GPC6 is essential for STAT3 phosphorylation in MDSCs. Finally,
since we showed that the oncogenic properties of TRF2 were depen-
dent on MDSC recruitment and immunosuppressive functions
(Figs 1–3) and that STAT3 phosphorylation is dependent on
HS3ST4 and GPC6, we evaluated the oncogenic properties of
▸Figure 3. Cancer cells directly activate MDSCs in a TRF2-dependent manner via the TLR2/MyD88/IL-6/STAT3 pathway that inhibit NK cell degranulation andcytotoxicity.
A, B Analysis of STAT3 phosphorylation by MSC2 cells after 18 h co-culture with BJcl2 overexpressing or compromised for TRF2 (A). Histograms of the pSTAT3 mean
fluorescence intensity (MFI) (B).
C–E Same experiment as in (A, B)  inhibitors: anti-MyD88 peptide inhibitor, anti-mouse TLR2 antibody, or lipopolysaccharide (LPS)-RS, an antagonist of TLR4 in (D)
and anti-mouse IL-6 or JAK1/2 inhibitor (Ruxolitinib) in (E).
F–H Schematic representation of the MDSC suppression assay (F). TRF2-overexpressing or TRF2-knockdown BJcl2 cells were co-cultured with MSC2 cells for
18 h  mouse IL-6 blocking antibody or ruxolitinib. After FACS sorting, MSC2 cells were co-cultured for 18 h with primed and purified NK cells before a 4 h
challenge with YAK-1. NK cell degranulation and IFN-c production were analyzed by FACS (G). Alternatively, a 4 h challenge with NIH3T3 cells was performed and
the ability of NK cells to kill NIH3T3 cells were determined by colorimetric analysis (AlamarBlue) (H).
Data information: Panels (G and H) show all points with mean  SEM corresponding to the percentages of each cell population among NK cells (G) or the percentage of
specific target lysis (H) (n = 3 independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001; Student’s t-test).
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HS3ST4 and GPC6 in tumor growth experiments. Their overexpres-
sion or downregulation affected neither cell proliferation nor clono-
genicity in vitro (Appendix Fig S1D and E). However, in xenograft
experiments using BJcl2 cells, downregulation of GPC6 or HS3ST4
decreased tumor weight (Fig 5I), delayed tumor occurrence
(Appendix Fig S1F), and reduced tumor growth (Appendix Fig
S1G). Conversely, overexpression of GPC6 or HS3ST4 increased
cancer tumorigenicity, accelerated tumor occurrence, and increased
tumor growth. In summary, TRF2 regulates the expression of three
HSPG genes that mediate MDSC recruitment and activation and pro-
mote tumorigenicity.
TRF2 changes glycocalyx structure, which triggers
MDSC activation
Because the above-mentioned results suggest that TRF2 regulates
the expression of a network of HSPG genes, we directly evaluated
whether TRF2 acts as a general remodeler of glycocalyx structure.
First, we analyzed the total heparan sulfate (HS) level by FACS
using the 10E4 antibody (van den Born et al, 2005). TRF2 overex-
pression increased the level of HS staining (Fig 6A), whereas TRF2
knockdown decreased it, indicating that TRF2 enhances HS synthe-
sis. Because HS is an essential component of the glycocalyx, we
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Figure 4. TRF2 regulates the expression of ITS-associated genes involved in glycocalyx synthesis.
A Gene expression analysis by quantitative polymerase chain reaction (qPCR) of TRF2 target genes following TRF2 overexpression or knockdown.
B, C Heatmap of H3K27ac (B) or H3K23me3 (C) peaks on the 4 kilobase (Kb) region around genomic ITSs (ENCODE data for the K562 cell line). The mean intensity of the
region is depicted in the histograms. ITSs are clustered depending of the peak mean intensity obtained from H3K27ac or H3K27me3 chromatin
immunoprecipitation sequencing (ChIP-seq) of the 4 Kb region. ITSs detected by ChIP-seq using an anti-TRF2 antibody are shown on the left.
D Specific qPCR for HS3SH4, GPC6, and VCAN ITSs after ChIP using an anti-H3K27ac antibody in TRF2-overexpressing or TRF2-knockdown BJcl2 cells. Data represent
fold enrichment of the H3K27ac level compared with the total H3 level.
Data information: Data represent n = 3 independent experiments with mean  SEM.
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investigated whether TRF2 modifies the glycocalyx and/or cell stiff-
ness by atomic force microscopy. By analyzing the force curves
obtained by cell nano-indentation, we measured both cell and
glycocalyx stiffness simultaneously (Appendix Fig S2A). Interest-
ingly, TRF2 overexpression increased both glycocalyx and cell stiff-
ness (Fig 6B). A visual indication of this TRF2-dependent cell
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Figure 5. HS3ST4, GPC6, and VCAN are effectors of the MDSC-dependent oncogenic properties of TRF2.
A Schematic representation of the Matrigel plug assay with BJcl2 cells knockdown for TRF2 target genes. Immune cell infiltration within the Matrigel plugs was
determined by FACS.
B–E Percentage of CD11bHi GR1Hi MDSCs (B), CD3- NKp46+ NK cells (C), NKp46+ CD107a+ NK cells (D), or CD69+ NK cells (E)
F–H Analysis of STAT3 phosphorylation by MSC2 cells after 18 h co-culture with BJcl2 overexpressing or compromised for TRF2 and the target genes (F). Histograms of
the pSTAT3 mean fluorescence intensity (MFI) of MSC2 cells when TRF2 was overexpressed and the target gene knocked down (G) and when both TRF2 and its
target gene were knocked down (H).
I Histograms of tumor weights on day 19 after implantation of subcutaneous xenografts containing BJcl2 cells overexpressing or knocked down for HS3ST4 or GPC6.
Data information: In (B–E), data are presented by box plots min to max showing all points with median corresponding to the percentages of each cell population among
CD45+ or NK cells (n = 8 mice per group; *P < 0.05 and ***P < 0.001; Mann–Whitney test). In (G and H), MFI of n = 3 independent experiment is normalized to controls
and represented as fold change of MFI (n = 3 independent experiments; *P < 0.05 and **P < 0.01; Student’s t-test). In (I), data are represented as mean  SEM (n = 8
mice per group; *P < 0.05, and **P < 0.01; Mann–Whitney test).
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Figure 6. TRF2 changes glycocalyx structure, which triggers MDSC activation.
A Analysis of heparan sulfate (HS) expression by FACS using the 10E4 antibody.
B Atomic force microscopic (AFM) analysis of glycocalyx and cell stiffness and glycocalyx length.
C AFM images showing the modulus heatmap (stiffness) in GFP-expressing or TRF2-overexpressing cancer cells. At each of the 128 × 128 force curve points,
corresponding to an area of 10 lm2, the AFM software automatically displays the Sneddon modulus analysis while scanning the sample. The color bar on the left of
the images shows a qualitative representation of the elastic map.
D Analysis of pSTAT3 levels in MDSCs after co-culture with GFP-expressing or TRF2-overexpressing cancer cells treated with or without sodium chlorate (NaClO3).
Data information: In (A), histograms representative (left panels) and MFIs from three independent experiments (*P < 0.05 and **P < 0.01; Student’s t-test) are
shown  SEM. In (B), box plots min to max showing all points with median represent four independent experiments, each performed using at least 20 cells (*P < 0.05;
Mann–Whitney test). For more details on the analysis procedure, see Materials and Methods section. In (D), data represents mean of n = 3 independent
experiments  SEM (***P < 0.001; Student’s t-test).
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mechanical property is provided in a heatmap of elastic cell
responses to the scanning atomic force microscopy probe (Fig 6C).
The modulus heatmap reveals that cells overexpressing TRF2
were stiffer than those expressing GFP. Analysis of the force
curves allows measurement of glycocalyx thickness, which was
significantly less for TRF2-overexpressing cells than GFP-expres-
sing cells (Fig 6B, right panel). To investigate whether these
global changes in glycocalyx structure are responsible for the
immunosuppressive role of TRF2, we globally inhibited glycoca-
lyx and HS synthesis in cancer cells using sodium chlorate
(Kang et al, 2013). As expected, treatment with sodium chlorate
was sufficient to inhibit the presence of cell-surface HS
(Appendix Fig S2B and C). We next evaluated its impact on
MDSC activation. Although sodium chlorate treatment in MSC2
cells did not alter STAT3 phosphorylation upon LPS stimula-
tion, which ruled out a direct effect of the treatment on MSC2
cells (Appendix Fig S2D), this treatment inhibited TRF2-depen-
dent STAT3 phosphorylation (Fig 6D and Appendix Fig S2E).
We conclude that TRF2-dependent changes in the glycocalyx
lead to MDSC activation.
TRF2 upregulation enhances the response to chemotherapies
targeting MDSCs
Because some conventional chemotherapeutic drugs (e.g., 5-fluor-
ouracil [5-FU], gemcitabine, and paclitaxel) can target MDSCs
(Apetoh & Vegran, 2011; Bruchard et al, 2013; Sevko et al, 2013),
TRF2 levels may modulate their efficacy. Therefore, we analyzed
the OS of patients according to TRF2 expression level and mode of
treatment. The prognoses of patients with high TRF2 expression
treated with chemotherapy, radiotherapy, or surgery were worse
than those of patients with low TRF2 expression (Figs 7A and
EV5B–E, and Dataset EV6), except for gastric cancer patients
treated with 5-FU, ovarian cancer patients treated with gemc-
itabine, and lung cancer patients treated with cisplatin, paclitaxel,
gemcitabine, or 5-FU (Fig 7A). In contrast, high TRF2 expression
seems to be associated with better survival (Figs 7A and EV5B–E).
This finding suggests that TRF2 overexpression may favor tumor
development in humans but enhance responses to chemotherapies
based on 5-FU or gemcitabine. To test this hypothesis, we
implanted B16F10 cells in the presence or absence of TRF2 over-
expression in immunocompetent mice treated with or without
5-FU (Fig 7B). As expected, TRF2 overexpression significantly
increased tumor volume (Fig 7C and D) and reduced OS (Fig 7E).
After 5-FU treatment in tumor-bearing mice, we observed that
tumor volume was reduced in both GFP control tumors and TRF2-
overexpressing tumors, with a larger effect on TRF2-overexpres-
sing tumors (Fig 7D). Following treatment, the volume of TRF2-
overexpressing tumors was comparable with that of control
tumors, suggesting that the effect of 5-FU was enhanced by TRF2
overexpression. Similarly, 5-FU treatment prolonged mouse OS
and prevented the decrease in OS induced by TRF2 over-
expression (Fig 7E). Taken together, these data suggest that
chemotherapy-based treatments that kill MDSCs (5-FU, gemc-
itabine, and paclitaxel) (Apetoh & Vegran, 2011; Bruchard et al,
2013; Sevko et al, 2013) abolished the pro-oncogenic effect of
TRF2 overexpression.
TRF2 upregulation in human malignancies is associated with
a poor prognosis, high expression of HSPG genes, and
MDSC infiltration
Finally, we investigated whether the relationships among TRF2
upregulation, HSPG gene expression, and MDSCs contribute to
patient outcome. Using public data obtained from the Cancer
Genome Atlas and KM-plotter (Sza´sz et al, 2016), we first con-
firmed that TRF2 is highly expressed in a large panel of human
cancers (Fig EV5F). Notably, very few TERF2 mutations were
detected in these cancers, suggesting that functional TRF2 is
required for tumorigenicity and that the tumorigenic properties of
TRF2 depend on its upregulation (Fig EV5G and Dataset EV5).
Among all histological types or pathological TNM stages of breast,
gastric, ovarian, and lung cancers (Fig 8A), OS was significantly
reduced in patients with tumors exhibiting high TRF2 expression.
According to hazard ratios (HRs), TRF2 overexpression was signifi-
cantly associated with an increased rate of mortality (Fig 8A,
Appendix Fig S3 and Dataset EV6), by more than twofold, in all
stages of gastric cancer (HR = 2.29), stage 3 lung adenocarcinoma
(HR = 2.17), and stage 2 lung small cell carcinoma (SCC;
HR = 2.03). Strikingly, this increase in mortality rate associated
with high TRF2 expression was even greater among stage 1 ovar-
ian and gastric cancers (HR = 6.31 and 4.73, respectively). Taken
together, these data suggest that TRF2 is associated with poor
prognosis and an increased mortality rate.
We examined OS as a function of the expression levels of TRF2
target genes (HS3ST4, GPC6, and VCAN). Even though some
patients are missing in the VCAN gene expression analysis (n = 631
instead of 876), we found that patients with high expression of
VCAN, HS3ST4, and GPC6 (collectively, HSPG genes) exhibited OS
rates similar to those of patients with high TRF2 expression (Figs 8B
and EV5H–J). Interestingly, we noticed similar OS between patients
with high expression (Hi) of HSPG and those with TRF2 Hi HSPG Hi
(high expression for TRF2, HS3ST4, GPC6, and VCAN), suggesting
epistatic relationships among these genes in human gastric tumors
(Figs 8C and EV5K). This relationship, together with the fact that
the numbers of patients were similar between the TRF2 Hi HSPG Hi
(n = 284) and HSPG Hi (n = 280) groups, indicates that most TRF2-
overexpressing tumors also exhibit upregulation of the three HSPG
genes and poor prognosis.
Next, we estimated MDSC infiltration by scoring the level of co-
expression of CD33 and C5AR as surrogate markers (Markiewski
et al, 2008; Nitta et al, 2013; Janelle et al, 2014). Most patients with
high TRF2 expression (gastric cancers) also exhibited marked MDSC
infiltration and reduced OS (Fig 8D and E). Consistent with the
epistatic relationships detected among high TRF2 levels, high HSPG
gene expression, high MDSC infiltration, and reduced OS, TRF2 Hi
MDSC Hi patients had OS rates identical to those of TRF2 Hi MDSC
Hi HSPG Hi and HSPG Hi MDSC Hi patients (Figs 8F and EV5L).
Moreover, TRF2 expression was positively correlated with high
HSPG gene expression (multiple regression, P = 6.7 × 1016;
Appendix Fig S4A) and MDSC infiltration (multiple regression,
P = 8.4 × 1025; Appendix Fig S4B). The expression levels of the
three HSPG genes were correlated with MDSC infiltration levels
(Spearman’s correlation, 8.62 × 1039) (Appendix Fig S4A–H).
Finally, we used chi-square analysis to compare variable
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independence between TRF2 expression and MDSC infiltration
(Fig 8D) or TRF2 expression, MDSC infiltration, and HSPG expres-
sion (Fig 8F) and found that TRF2 expression, MDSC infiltration,
and expression of HSPG target genes (HS3ST4, GPC6, and VCAN)
appear to be interdependent (Appendix Fig S4I and J).
Overall, we conclude that high TRF2 expression in a large cohort
of gastric cancer patients was associated with worse prognoses in
an epistatic relationship with the expression of the three HSPG
genes regulated by TRF2.
Discussion
In this study, we revealed a mechanism by which cancer cells
recruit and activate MDSCs via the TLR2/MyD88/IL-6/JAK1/2
pathway, based on upregulation of the telomere protein TRF2. We
also demonstrated that this TRF2-dependent regulation of MDSCs
acts as a general suppressor of the immune response by inhibiting
NK and T cell responses, establishing a direct link between
cancer-associated telomere changes and the immunosuppressive
tumor microenvironment. Remarkably, the role of TRF2 in this
process is not to protect telomeres but to regulate the expression
of three genes involved in HSPG biosynthesis (HS3ST4, GPC6, and
VCAN). In fact, this role of TRF2 in HSPG gene expression is cen-
tral to shaping the glycocalyx, because TRF2 overexpression pro-
foundly changes its overall structure, increasing its stiffness and
reducing its length. The roles of TRF2 in HSPG biosynthesis and
MDSC control may have high clinical relevance because the TRF2
upregulation observed in a large number of human cancer
patients was correlated with high HSPG expression, MDSC infiltra-
tion, and poor prognosis in an epistatic relationship. Moreover,
we provide evidence that the tumoral expression level of TRF2 is
associated with an increased mortality rate and decreased OS and
could be used as a surrogate marker for the efficacy of chemothera-
pies targeting MDSCs.
The finding that HS3ST4 and GPC6 are required for MDSC
recruitment can be explained by glycocalyx changes that modify
micro-gradients of the cytokines, chemokines, and growth factors
involved in immune cell recruitment (Simon Davis and Parish,
2013; Knelson et al, 2014). The glycocalyx changes induced by
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Figure 7. TRF2 upregulation enhances the response to chemotherapies targeting MDSC.
A Kaplan–Meier curves for overall survival of chemotherapy-treated patients according to the TRF2 expression level (KM-plotter, http://kmplot.com/analysis/index.
php?p=background).
B–E Schematic representation of the mouse experiment. Immunocompetent mice were subcutaneously engrafted with B16F10 cells with or without TRF2
overexpression and treated with three intraperitoneal injections of 50 mg/kg 5-FU. The tumor volume was determined every 2 days using a caliper, and growth
curves over time (C) and tumor volume were determined on day 19 and represented using box plots min to max showing all points with median (D). Overall
survival was also determined (E).
Data information: in (A), the optimal cut-off is determined on KMplot. The P-value (log-rank test), the hazard ratio and number of patients are indicated. In (B-C), data
represent mean values  SEM (n = 8 mice per group; *P < 0.05 and **P < 0.01; Mann–Whitney test). In (D), data are represented by box plots min to max showing all
points with median (n = 8 mice per group; *P < 0.05 and **P < 0.01; Mann–Whitney test).
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TRF2 might have other oncogenic consequences, for example, by
favoring neoangiogenesis (Zizza et al, 2019) or tissue remodeling.
The finding that VCAN upregulation controlled MDSC activation is
consistent with a previous report showing that the proteoglycan
Versican, encoded by VCAN, acts as a TLR2 ligand (Kim et al, 2009)
and that TLR2 signaling activates the immunosuppressive function
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Figure 8. TRF2 upregulation in human malignancies is associated with a poor prognosis, high expression of HSPG genes, and MDSC infiltration.
A Kaplan–Meier curves for overall survival of patients at all stages of cancers (breast, gastric, ovarian, and lung cancer) depending on TRF2 expression level (KMplot,
http://kmplot.com/analysis/index.php?p=background).
B–D The overall survival of gastric cancer patients (all stages) was analyzed depending on TRF2 and its target gene expression level (HS3ST4, GPC6, and VCAN
collectively named the HSPG genes) or with MDSC level (Lo or Hi), determined as the mean expression level of CD33 and C5AR, using KMplot, http://kmplot.com/ana
lysis/index.php?p=background.
E Repartition of number of gastric cancer patients depending on TRF2 and MDSC classification.
F Overall survival of gastric cancer patients (all stages) analyzed depending on TRF2, HSPG genes (HS3ST4, GPC6, and VCAN) and MDSC level (Lo or Hi).
Data information: For all panels, the optimal cut-off is determined on KMplot. The P-value (log-rank test), the hazard ratio and number of patients are indicated.
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of MDSCs (Skabytska et al, 2014) via an IL-6 autocrine pathway
(Chalmin et al, 2010).
We showed in a previous study that TRF2 overexpression in
cancer cells enhances tumorigenicity and that NK cell inhibi-
tion, by depleting NK cells in vivo, was the main target of a
TRF2-dependent increase in tumorigenicity (Biroccio et al, 2013).
Since the oncogenic role of TRF2 was detected using both
immunocompetent and immunodeficient mouse models, and NK
cell recruitment and activation rescue were observed when
MDSCs were depleted in both models, NK cells are arguably
major target cells of MDSC activation controlled by TRF2 in
cancer cells.
The increase of STAT3 phosphorylation and immunosup-
pressive capacity of MDSCs on NK cell degranulation and cyto-
toxicity (Fig 3), which were induced by TRF2 overexpression
in cancers in a TLR2/MyD88-dependent manner, required IL-6
secretion and JAK1/2 activity. This finding suggests that changes
in HSPG expression are regulated by TRF2 signaling to induce
an immunosuppressive autocrine loop via IL-6/JAK1/2/STAT3
signaling.
We also explored the mechanism by which TRF2 controls the
expression of the three HSPG genes. These genes each contain an
ITS that serves as a binding site for TRF2. Upon binding, TRF2
induced a change in chromatin structure at the ITS, as revealed by
the enrichment of H3K27ac, an activating histone mark (Villar et al,
2015); this suggests that ITSs behave as TRF2-dependent enhancer
elements that activate the expression of neighboring genes. In agree-
ment with this model, TRF2 interacts with the histone acetyl trans-
ferase p300, which is responsible for histone acetylation at
enhancers (Her & Chung, 2013).
We provided the following evidence that this TRF2-dependent
mechanism of MDSC regulation by HSPG genes plays an important
role in human cancers: (i) immunodepletion of MDSCs by anti-
bodies was sufficient to reverse the oncogenic and pro-metastatic
properties of TRF2 in mouse models of tumor formation (Fig 2); (ii)
high TRF2 expression was observed in several human malignancies
and found to be associated with poor prognosis (Fig 8); (iii) high
expression of TRF2 effector genes (HS3ST4, GPC6, and VCAN) and
MDSC infiltration was found to be associated with poor prognosis
in an epistatic relationship with high TRF2 expression (Fig 8); (iv)
the cell-surface HS (Qazi et al, 2016) or HSPG expression level
(Wang et al, 2009; Knelson et al, 2014; Dinccelik Aslan et al, 2015)
was crucial for tumor invasion and metastasis and was associated
with poor survival (Gan et al, 2010; Matas-Rico et al, 2016) (Figs 2
and 8); and (v) TRF2-dependent glycocalyx changes recruited and
activated MDSCs as well as the expression of the immunosuppres-
sive effectors il-10, tgf-b, and Arg-1, molecules responsible for
NK and T cell inhibition, in the tumor microenvironment (Fig 2)
(Platonova et al, 2011; Kodumudi et al, 2012; Fujimura et al, 2014;
Kumar et al, 2016a). Thus, TRF2 emerges as a potential target for
innovative anti-cancer therapies. In particular, specific inhibition of
TRF2 may show a synergistic effect with strategies targeting
immune checkpoints.
Another clinical implication of our results concerns the effi-
ciency of conventional chemotherapies. The negative effects of
TRF2 overexpression on OS can be reduced following 5-FU treat-
ment in gastric cancer, gemcitabine treatment in ovarian cancer,
and paclitaxel-based chemotherapy in lung cancer, three
compounds that target MDSCs (Apetoh & Vegran, 2011; Bruchard
et al, 2013; Sevko et al, 2013), which suggests that chemotherapy
efficiency is enhanced in patients with high TRF2 expression.
Accordingly, the reduction in tumor volume and increase in OS
observed in mice bearing TRF2-overexpressing tumors observed
after treatment with 5-FU suggest that TRF2 overexpression
enhances the efficiency of 5-FU. In line with the MDSC depletion
data, the increased response to 5-FU may be linked to better
elimination of MDSCs, in turn allowing reactivation of the immune
system. Thus, the level of TRF2 expression might be an interesting
surrogate marker for chemotherapy responses.
Taken together, the results of this study identify an immunosup-
pressive pathway for MDSCs that links the telomeric protein TRF2
to glycocalyx reshuffling, suggesting novel strategies to prevent
immunosurveillance escape and enhance the efficacy of cancer
therapies (Fig EV5A).
From an evolutionary perspective, there is a striking similarity
between (i) our finding that the genes encoding glycocalyx
components involved in immunosuppression in cancer cells are
regulated by TRF2 and (ii) the antigenic variation employed by
various pathogens to bypass the host immune response, involv-
ing the regulation of genes encoding plasma membrane proteins
by TRF2 homologs (Jehi et al, 2014). This similarity suggests a
conserved mechanism that couple telomere status to cell-surface
composition, which is likely to ensure efficient coordination
between telomere changes and the interaction of cells with
their environment.
Materials and Methods
Cell culture and viral transduction
B16F10 (obtained from the ATCC, Manassas, VA), HEK293T,
NIH3T3, or the human fibroblast BJ rendered immortal and tumori-
genic by SV40 small t and large T, hTERT overexpression and
RasV12 overexpression called Bjcl2 (Biroccio et al, 2013) were
grown in DMEM (Invitrogen) supplemented with 10% of FCS and
1% of penicillin–streptomycin at 37°C with 5% CO2. MSC2 (ob-
tained from Pr Ghiringhelli laboratory) or YAK-1 (obtained from Pr
Vivier laboratory) was cultured in RPMI medium (Thermo Fisher
Scientific) supplemented with 10% FCS and 1% of penicillin–strep-
tomycin (Invitrogen) at 37°C with 5% CO2. Mycoplasma test was
performed every 3 months, and experiments are performed only on
mycoplasma negative cells. To create lentiviruses, transient trans-
fection with 293T cells was performed as described previously
(Biroccio et al, 2013).
Target Species Number Sequence
TERF2 Human #1 CATTGGAATGATGACTCTGAA
TERF2 Human #2 CCTGGAGAGAAGAATCCCAAA
HS3ST4 Human #1 CCCATCAGTTTGATTCAATTA
GPC6 Human #1 GCTTCCTCTTTCCTTCAGCTA
VCAN Human #1 CCGGGTGAATTTCTCCGCATC
Terf2 Mouse #1 CCTTGGAATCAGCTATCAATG
Terf2 Mouse #2 CAAGGAGGCTGCTGTCATTAT
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Colony assay
200 transduced cells per well were seeded in 6-well plate. After
10 days, colonies were washed with PBS, fixed for 30 min with
acetic acid/methanol, and revealed by crystal violet staining for
30 min. Colonies were then determined by manual counting.
AlamarBlue
Cells were seeded (5 × 103 cells per well in 200 ll) in a 96-well flat-
bottom plate. 10 ll of AlamarBlue (Bio-Rad) was added 24 h later,
and the absorbance was measured at 570 and 600 nm for 36 h in a
Spectrostar Nano plate reader (BMG Labtech). In the case of NK cell
killing assay, the NK cells were added for 4 h before washing of the
wells and addition of AlamarBlue. The oxydoreduction of the col-
orant was determined 8 h after. In both experiments, the oxidation–
reduction percentage of AlamarBlue was determined as described
by the manufacturer.
Animals
Experiments are performed on 8- to 12-week-old female C57Bl6J
mice and NMRI Nude mice from Janvier Labs (France) or from 6- to
12-week-old male CD1 nu/nu from Charles River (Italy). All mouse
experiments were conducted according to local and international
institutional guidelines and were approved by either the Animal
Care Committee of the IRCAN and the regional (CIEPAL Cote
d’Azur #187 and #188) and national (French Ministry of Research
#03482.01/02482.2 and # 02973.01/02973.2) authorities.
Tumor growth, metastasis assay, and Matrigel plugs assay
experiments
Cells were injected subcutaneously in the back of mice at 106 cells/
mouse (n = 8 mice per group). The tumor appearance was evalu-
ated by palpation, the tumor size was measured every 2 days in
three dimensions by caliper and tumor volume calculated using the
hemi-ellipsoid formula: p × (L × l × h)/6, where L corresponds to
the length, l to the width, and h to the height the tumor,
respectively. Tumor, Matrigel plugs, or lung infiltrating cells were
collected after enzymatic dissociation by Dispase (Corning), collage-
nase A (Roche), and DNAse I (Roche) digestion for 30 min at 37°C.
After washes in PBS, cells were fixed in formaldehyde 0.5% and the
quantity of GFP+ infiltrating cells (metastatic B16F10 cells) was
determined by FACS (ARIA III cytometer, DIVA6 software (BD Bio-
sciences) and FlowJo 10 (LLC)). When indicated, mice were treated
with three intraperitoneal injections of 50 mg/kg of 5-FU (days 10,
13, and 16) or with intraperitoneal injections of 200 lg in 100 ll of
rat IgG2b isotopic control or anti-GR1 antibody (BioXcell).
Cells were injected into the hind leg muscles of mice at 105 cells/
mouse or 5 × 105 cells/mouse (n = 6 mice per group). The tumor
appearance was evaluated by palpation, the tumor size was mea-
sured three times a week in two dimensions by a caliper, and tumor
weight was calculated using the following formula: a × b2/2, where
a and b are the long and short diameter of the tumor, respectively.
For Matrigel assay (Biroccio et al, 2013), 106 cells/mouse in
100 ll of PBS and complemented with 400 ll of Matrigel growth
factor reduced (Corning) were inoculated subcutaneously into the
back under isoflurane anesthesia. 5 days after, mice were sacrificed
and Matrigel plugs were harvested. Infiltrating cells were collected
after enzymatic dissociation as described earlier and stained with
directly coupled antibodies for 30 min at 4°C after saturation with
Fc-Block anti-CD16/CD32 antibodies (clone 2.4G2) for 15 min on
ice. After washes in 0.5 mM EDTA 2% FCS PBS and fixation with
0.5% FA, cells were analyzed using an ARIA III cytometer with
DIVA6 software (BD Biosciences) and FlowJo 10 (LLC).
For metastasis assay, adult C57Bl6j female mice received a single
intravenous tail vein injection of 1 × 105 B16F10 GFP or B16F10
overexpressing TRF2-GFP cells. The mice were subsequently intra-
peritoneally injected every 3 days with 200 lg in 100 ll of either
isotype (rat IgG2b) or anti-GR-1 (RB6-8C5) antibodies from BioXcell.
The mice were euthanized 21 days after intravenous injection, and
lungs were inflated and perfused through the trachea with 4%
paraformaldehyde (PFA), fixed overnight, transferred to 70%
ethanol, and subsequently embedded in paraffin. Metastasis burden
was determined for each animal by macroscopic quantification of
lung nodules (counting). Tumors histology was examined on 5-lm
tissue section stained with hematoxylin and eosin (H&E).
Table of antibodies
Specificity Company Clone Species Isotype Fluorochrome Reference
Anti-Ly6G (Gr1) eBioscience RB6-8C5 rat IgG2b, k PE 12-5931-82
Anti-CD107a FITC BD Biosciences 1D4B Rat IgG2a/k FITC 553793
Anti-CD107a FITC BD Biosciences 1D4B Rat IgG2a/k FITC 553793
Anti-CD107b BD Biosciences ABL-93 Rat IgG2a/k FITC 558758
Anti-CD11b BD Biosciences M1/70 Rat IgG2b APC-H7 550993
Anti-CD11c BD Biosciences HL3 Hamster IgG1 FITC 557400
Anti-CD19 FITC BD Biosciences 1D3 Rat IgG2a, j FITC 553785
Anti-CD335 (NKp46) BD Biosciences 29A1.4 Rat IgG2a PE 560757
Anti-CD45 BD Biosciences 30-F11 Rat IgG2b PerCP 557235
Anti-CD69 PE-Cy7 BD Biosciences H1.2F3 Hamster IgG1/K PE-Cy7 552879
Anti-CD8a BD Biosciences 53-6.7 Rat IgG2a,K BV650 563152
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Table of antibodies (continued)
Specificity Company Clone Species Isotype Fluorochrome Reference
Anti-IFN-gamma BD Biosciences 4S.B3 Mouse IgG1/K PE 554552
Anti-IFN-gamma BD Biosciences XMG1.2 Rat IgG1/K PE 554412
Anti-NK-1.1 BD Biosciences PK136 Mouse IgG2a/k APC 550627
Anti-NK-1.1 Biolegend PK136 Mouse IgG2a, j APC 108710
Anti-NKp46 CD335 BD Biosciences 29A1.4 Rat IgG2a Alexa 647 560755
Anti-CD107a BD Biosciences 1D4B Rat SD IgG2a, j V450 560648
Anti-CD11b Biolegend M1/70 Rat IgG2b, j BV605 101237
Anti-CD11c Biolegend N418 Armenian Hamster IgG PE/dazzle 117347
Anti-CD19 Biolegend 6D5 Rat IgG2a, j BV510 115545
Anti-CD19 Biolegend 6D5 Rat IgG2a, j BV785 115543
Anti-CD25 eBioscience PC 61.5 Hamster IgG1 lambda PE-Cy7 25-0251-82
Anti-CD335 (NKp46) BD HORIZON 29A1.4 Rat IgG2a, j BV510 563455
Anti-CD3e BD Biosciences 145-2C11 Hamster IgG1, j FITC 553062
Anti-CD3e Biolegend 145-C11 Armenian Hamster IgG PerCP 100302
Anti-CD4 BD Biosciences GK1.5 Rat IgG2b, j PE 553730
Anti-CD4 Life Technologies Monoclonal Rat IgG2a PE-AF700 MCD0424
Anti-CD45 BD Biosciences 30-F11 Rat IgG2b, j AF700 560510
Anti-CD8a BD Biosciences 53-6.7 Rat LOU IgG2a, j PerCP-Cy5.5 551162
Anti-F4/80 Biolegend BM8 Rat IgG2a, j PerCP-Cy5.5 123128
Anti-F4/80 Biolegend BM8 Rat IgG2a, j BV510 123135
Anti-Ly6C eBiosciences HK1.4 Rat IgG2c, j APC-eFluor780 47-5932-82
Anti-Ly6C/Ly6G (Gr-1) Biolegend RB6-8C5 Rat IgG2b, j PE 108408
Anti-Ly6C/Ly6G (Gr-1) BD Biosciences RB6-8C5 Rat IgG2b, j PE 553128
Anti-Ly6C/Ly6G (Gr-1) Biolegend RB6-8C5 Rat IgG2b, j BV421 108434
Anti-Ly6G BD Biosciences 1A8 Rat LEW IgG2a, j PE-Cy7 560601
Anti-Ly6G Biolegend 1A8 Rat IgG2a, j BV421 127627
Anti-Ly6G (Gr-1) BD Biosciences 1A8 Rat LW IgG2a, j BV711 563979
Anti-stat3 (pY705) BD PhosphoFlow 4/P STAT3 Mouse IgG2a, j AF 647 557815
Anti-h HS3ST4 Biotechne #712010 Mouse IgG1 Uncoupled MAB6085
Anti-h GPC6 Biotechne #348701 Mouse IgG1 Uncoupled MAB2845
Anti-h GPC6 Abcam Polyclonal Rabbit IgG Uncoupled Ab170523
Anti-h VCAN Abcam EPR12277 Rabbit IgG Uncoupled Ab170480
Stiffness determination by atomic force microscopy
The experiments were performed in Leibovitz’s medium (Life Tech-
nologies) supplemented with heat-inactivated 10% fetal bovine
serum (FBS) on cells grown on 50-mm Willco glass-bottom dish.
After thermal stabilization, for each sample, a minimum of 20 cells
were analyzed using the “Point and Shoot” method, collecting at
least 100 force–distance curves at just as many discrete points (on
average five points for each cell in the perinuclear area). After deter-
mining both the deflection sensitivity of the system in the Lei-
bovitz’s medium using a clean Willco glass-bottom dish and the
spring constant of the cantilever by means of the thermal tune
method, force–distance curves were collected on samples using a
velocity of 1 lm/s, in relative trigger mode and by setting the trigger
threshold to 400 pN. The apparent Young’s modulus was calculated
using the NanoScope Analysis 1.80 software (Bruker Nano Surfaces,
Santa Barbara, CA, USA) applying to the force curves, after the base-
line correction, the Hertz spherical indentation model using a Pois-
son’s ratio of 0.5. For each force curve, after finding the contact
point, the force fit boundaries to perform the fit were chosen
between 0% and the percentage corresponding to the point in which
a clear change in the slope of the curve was observed (y0 in Fig 5).
This first fit was used to obtain the apparent Young’s modulus of
the glycocalyx. By interpolation, the value |x0|, corresponding to the
thickness of the cell brush, was found. The apparent Young’s modu-
lus of the cell body was obtained using, on the same force curve, fit
boundaries between the percentage corresponding to y0 and 70%.
To avoid any tilt effect due to the base correction step, only the
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force curves having their maximum value at 400 pN were consid-
ered for performing the fit, and then, only the apparent Young’s
modulus values corresponding to a fit with R2 > 0.75 were consid-
ered. The cells mechanical proprieties were obtained by atomic
force microscopy using a Bioscope Catalyst (Bruker Nano Surfaces,
Santa Barbara, CA, USA), coupled with an inverted optical micro-
scope (Leica DMI6000B, Leica Microsystems Ltd., UK). The force–
distance curves needed to calculate the apparent Young’s modulus
were collected using a Borosilicate Glass spherical tip (5 lm of
diameter) mounted on a cantilever with a nominal spring constant
of 0.06N/m (Novascan Technologies, Ames, IA USA). The Sneddon
modulus heat maps were captured with a SNL-D probe (Bruker
Nano Surfaces, Santa Barbara, CA, USA) in Peak force tapping using
a peak force set point of 600 pN and a peak force frequency of
0.25 kHz.
ITS search and mammalian ITS comparison
ITSs motifs were searched on the hg19 genome. We first used
BLAST+ (PMID: 20003500) to find all the patterns T2AG3 repeated
at least four times and with 1 maximum mismatch per pattern
T2AG3. We then used a Python script to merge the positions of dis-
tant ITSs closed to < 400 nucleotides and create the final bed file
containing a total of 483 ITSs. Mammalian ITSs were identified
using the same criteria.
ITSs were annotated using “Bedtools window” as follows: the
closest gene (first gene), genes present in a  50 Kb interval, and
genes present in a  200 Kb interval. For each species, the ITS
file was compared with the refGene file. For each gene, the tran-
scription start (txStart) and end position (txEnd) were chosen. The
position of each ITS was compared with the positions of the
genes. Results were summarized using a homemade Python script
in files containing the ITS ID, ITS position, closest gene, genes
present within the  50 Kb interval, and genes present within the
 200 Kb interval.
Data were compared with published ChIP-seq data (H3K4me3,
H3K27ac) (ENCODE). For each species, overlapping regions were
identified between ITS and H3K27ac files, ITS and H3K4me3 files,
and ITS and H3K4me3 H3K27ac files thanks to a homemade Python
script using the Pybedtools library with “BedTool.intersect()”
method. Statistical analysis was performed using Pybed-
tools.BedTool: “randomstats”. A thousand iterations were chosen,
corresponding to a P-value of 0.001.
TCGA and overall survival analysis
Standardized TCGA data were obtained from Broad Institute TCGA
Genome Data Analysis Center (2016, https://doi.org/10.7908/
c11g0km9) The expression level and mutations of TERF2 in 30
cancer type were analyzed using the Genomic Data Commons
cBioPortal website (http://www.cbioportal.org/). Data were col-
lected to be analyzed using Prism 7.0 (GraphPad).
Overall survival (OS) analysis was performed using Kaplan–
Meier plotter (KM-plotter) website (http://kmplot.com) following
recommendations of the authors (Sza´sz et al, 2016) and discus-
sions with Dr Bala´zs Gy}orffy. For each cancer type (lung, prostate,
gastric, or breast), patient OS was determined based on TERF2
expression level. The optimal cut-off and the median of survival
were determined by KM-Plotter for each cohort. No dataset was
excluded. Down-staging analysis was performed depending on
tumor stage, treatment, or TRF2 target gene as indicated. In all
cases, P-values and hazard ratios (HR) were determined by KM-
plotter and Chi2 analysis and curves were generated using Prism
7.0 (GraphPad).
MDSC co-culture and NK cell degranulation and killing
assay in vitro
Primary NK cells (CD45+, CD3-NKp46+) were FACS sorted from
c57Bl/6j naı¨ve splenocytes previously stimulated in vivo for 18 h
by an intraperitoneal injection of 150 lg of Poly I:C) (Invivogen,
Toulouse, France). In parallel, a co-culture was carried out for
18 h with transduced B16F10 or BJcl2 and MSC2 cells as indi-
cated (Figs 3 and EV3). The MSC2 cells are then sorted by FACS
(Gr-1+ CD11b+). Purity controls on the post-sort fractions are
performed (Fig EV3). Finally, sorted NK and MSC2 were co-
cultured for 18 h, in presence or not of mouse IL-6 blocking anti-
body or JAK1/2 inhibitor (Ruxolitinib) (see section Inhibitors).
Then, the degranulation capacity of NK cells was tested after chal-
lenge with YAK-1 (NK targets) and the killing capacity of NK cells
was analyzed using NIH3T3 as target cells. YAK-1 cells are added
to the culture for 4 h in presence of monensin and brefeldin (BD
Bioscience) at the effector/target ratio of 5:1 or 10:1. Degranula-
tion activity of the NK cells is then measured by FACS by the
anti-CD107a and IFN-c staining. Alternatively, NIH3T3 cells are
plated in 96-well plates and, after adhesion of NIH3T3 cells, the
NK/MSC2 co-culture was added at the effector/target ratio 10:1
for 4 h. Wells were then washed, and the viability of remaining
NIH3T3 cells was assessed using AlamarBlue colorimetric method
(see section AlamarBlue).
Intranuclear phospho-STAT3 staining
MSC2 cells or cells from Matrigel plugs or mouse tumors were
harvested and fixed with PFA 4% for 30 min at room tempera-
ture. Cells were washed in perm/wash buffer (BD Biosciences)
and resuspended in buffer III (BD Biosciences) for 30 min on ice.
After washes, cells are resuspended in perm/wash buffer and
saturated with Fc-Block. Then, anti-GR1, anti-CD11b, and anti-
pSTAT3 or isotypic controls (BD Biosciences) were directly added
and incubated for 30 min. After washes, the staining is analyzed
on a FACS ARIA III (BD Biosciences). pSTAT3 of MSC-2 cells was
determined after 24 h treatment with 100 ng/ml LPS (Invivogen),
with or without NaClO3 (50 mM), after 24 h co-culture with
cancer cell or conditioned media from cancer cell overexpressing
or compromised for TRF2 and TRF2 target genes (VCAN, HS3ST4,
or GPC6).
Toll-like receptor pathway and IL-6/JAK-STAT pathway inhibitors
Using MSC2 cells pretreated with LPS (100 ng/ml during 24 h), opti-
mal doses for each inhibitor have been determined by analyzing
pSTAT3 level by FACS. Then, the optimal doses (LPS-RS 30 ng/ml,
anti-mTLR2 antibody 30 ng/ml, anti-MyD88 peptide 10 lM, anti-
mIL-6 250 ng/ml, or ruxolitinib 10 lM) were applied in MSC2/
cancer cell co-culture assay.
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Heparan sulfate analysis by flow cytometry
Cells were harvested with cold PBS–EDTA 3 mM and adjusted at
1 × 106 cells/ml. After Fc-Block saturation, 10 lg of anti-heparan
sulfate (Clone 10E4 from Amsbio) per million of cells were added
for 30 min on ice. After washes and incubation with specific APC
coupled anti-IgM secondary antibody (eBioscience), cells were
washed and analyzed with a FACS ARIA III (BD Biosciences). The
inhibition of heparan sulfate synthesis by sodium chlorate (NaClO3)
was tested by treating the cells with increasing doses of NaClO3 and
analyzing the 10E4 staining as described. The optimal doses of
50 mM were determined and used for experiments.
ChIP-qPCR
1 × 107 transduced BJcl2 cells are fixed with 1% formaldehyde for
10 min at room temperature. The reaction is stopped by 1M glycine.
Nuclei are extracted using nuclear extraction buffer (50 mM Tris–Cl
pH 8, 10 mM EDTA, 1% SDS, protease inhibitors) and then soni-
cated using Bioruptor (Diagenode) for 14 cycles alternating 30 s of
sonication 30 s without sonication. Chromatin fragmentation, previ-
ously washed using the PCR Clean-Up kit (Promega), was checked
(500 bp) by migration on a 1% agarose gel. 30 ll of the sonicated
DNA is recovered before IP called “Input.” Chromatin IP is carried
out overnight at 4°C with stirring (see antibody list below). DNA is
immunoprecipitated using magnetic beads coupled to the G protein
(Thermo Fisher Scientific) and washed. DNA–protein interaction
was broken by addition of 5M NaCl overnight at 65°C. DNA extrac-
tion is carried out by phenol/chloroform method. DNA derived from
the ChIP is amplified by qPCR using different pairs of primers specif-
ically targeting the ITS region of the different genes:
HS3ST4 (50CTGGGAGACTTTGTGCGTCT30-30CTTGAGCTTCCATCCT
CTGG50),
VCAN (50GCGGATCATGAGGTCAGGAG30-30ACTGGGACTACAGGCT
AGGG50),
GPC6 (50TCGCTAATCGATGCATAACC30-30TGCTGAAGGCTGTTGA
ACTT50).
The enrichment of the ChIP was standardized with respect of his-
tone H3 amount present at the level of the ITS but also in relation to
the internal controls (input and GAPDH promoter).
RT–qPCR
1 × 106 cells are lysed to extract the RNAs using RNeasy Plus Mini
kit (Qiagen). RNAs concentration and quality are determined by
Nanodrop 2000/2000c (ThermoFisher). Reverse transcription (RT)
from 1 lg of RNA was performed using Applied Biosystems reverse
transcription kit in a T100 thermocycler (Bio-Rad). qPCRs were
made on cDNAs obtained using ROCHE’s Fast universal Sybr Green
master (ROX) on a StepOne plus thermocycler (Applied Biosystems)
using primers described below.
Statistical analysis
Reasonable sample size was chosen to ensure adequate reproducibil-
ity of results and was based on our previous studies. Mouse experi-
ments are performed on n = 8 individuals (or 5 in some cases) as
indicated in Fig legends. Mice were equally divided for treatments
and controls. A formal randomization tool was not employed. For
survival analysis, patients were separated based on optimal cut-off of
the expression value of the marker determined using KMplot. Animal
data are stopped in end point analysis (time point indicated in each
Fig legend) before to reach the ethical end point fixed in advance fol-
lowing the international ethical recommendation on mouse care (see
details in mouse experiment procedure). No data were excluded. No
outliers were excluded. Statistical tests were all performed with
GraphPad Prism 7 software including the Student’s t-test, the Mann–
Whitney test, the log-rank test, Pearson correlation, chi-square analy-
sis, and two-way ANOVA tests. The corresponding tests and P-values
are mentioned in the legend of each Figure.
Expanded View for this article is available online.
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